# Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen

> **NCT02739477** · PHASE2 · TERMINATED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 2 (actual)

## Conditions studied

- Ebola Virus Survivor

## Interventions

- **DRUG:** Favipiravir

## Key facts

- **NCT ID:** NCT02739477
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** End date of epidemic
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739477, "Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02739477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*